Cargando…
Genotype and Intensive Pretreatment Influence Outcome of Acute Myeloid Leukemia Patients Treated With Venetoclax in Combination With Hypomethylating Agents or Low-dose Cytarabine: “Real World” Data From Germany
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365332/ https://www.ncbi.nlm.nih.gov/pubmed/35966764 http://dx.doi.org/10.1097/HS9.0000000000000759 |
| _version_ | 1784765322929111040 |
|---|---|
| author | Braitsch, Krischan Schmalbrock, Laura K. Jung, Paul Bumeder, Irmgard Kiewe, Philipp Hecker, Judith S. Verbeek, Mareike Westermann, Jörg Bullinger, Lars Keller, Ulrich Bassermann, Florian Krönke, Jan Götze, Katharina S. Rieger, Kathrin |
| author_facet | Braitsch, Krischan Schmalbrock, Laura K. Jung, Paul Bumeder, Irmgard Kiewe, Philipp Hecker, Judith S. Verbeek, Mareike Westermann, Jörg Bullinger, Lars Keller, Ulrich Bassermann, Florian Krönke, Jan Götze, Katharina S. Rieger, Kathrin |
| author_sort | Braitsch, Krischan |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9365332 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-93653322022-08-11 Genotype and Intensive Pretreatment Influence Outcome of Acute Myeloid Leukemia Patients Treated With Venetoclax in Combination With Hypomethylating Agents or Low-dose Cytarabine: “Real World” Data From Germany Braitsch, Krischan Schmalbrock, Laura K. Jung, Paul Bumeder, Irmgard Kiewe, Philipp Hecker, Judith S. Verbeek, Mareike Westermann, Jörg Bullinger, Lars Keller, Ulrich Bassermann, Florian Krönke, Jan Götze, Katharina S. Rieger, Kathrin Hemasphere Letter Lippincott Williams & Wilkins 2022-08-09 /pmc/articles/PMC9365332/ /pubmed/35966764 http://dx.doi.org/10.1097/HS9.0000000000000759 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
| spellingShingle | Letter Braitsch, Krischan Schmalbrock, Laura K. Jung, Paul Bumeder, Irmgard Kiewe, Philipp Hecker, Judith S. Verbeek, Mareike Westermann, Jörg Bullinger, Lars Keller, Ulrich Bassermann, Florian Krönke, Jan Götze, Katharina S. Rieger, Kathrin Genotype and Intensive Pretreatment Influence Outcome of Acute Myeloid Leukemia Patients Treated With Venetoclax in Combination With Hypomethylating Agents or Low-dose Cytarabine: “Real World” Data From Germany |
| title | Genotype and Intensive Pretreatment Influence Outcome of Acute Myeloid Leukemia Patients Treated With Venetoclax in Combination With Hypomethylating Agents or Low-dose Cytarabine: “Real World” Data From Germany |
| title_full | Genotype and Intensive Pretreatment Influence Outcome of Acute Myeloid Leukemia Patients Treated With Venetoclax in Combination With Hypomethylating Agents or Low-dose Cytarabine: “Real World” Data From Germany |
| title_fullStr | Genotype and Intensive Pretreatment Influence Outcome of Acute Myeloid Leukemia Patients Treated With Venetoclax in Combination With Hypomethylating Agents or Low-dose Cytarabine: “Real World” Data From Germany |
| title_full_unstemmed | Genotype and Intensive Pretreatment Influence Outcome of Acute Myeloid Leukemia Patients Treated With Venetoclax in Combination With Hypomethylating Agents or Low-dose Cytarabine: “Real World” Data From Germany |
| title_short | Genotype and Intensive Pretreatment Influence Outcome of Acute Myeloid Leukemia Patients Treated With Venetoclax in Combination With Hypomethylating Agents or Low-dose Cytarabine: “Real World” Data From Germany |
| title_sort | genotype and intensive pretreatment influence outcome of acute myeloid leukemia patients treated with venetoclax in combination with hypomethylating agents or low-dose cytarabine: “real world” data from germany |
| topic | Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365332/ https://www.ncbi.nlm.nih.gov/pubmed/35966764 http://dx.doi.org/10.1097/HS9.0000000000000759 |
| work_keys_str_mv | AT braitschkrischan genotypeandintensivepretreatmentinfluenceoutcomeofacutemyeloidleukemiapatientstreatedwithvenetoclaxincombinationwithhypomethylatingagentsorlowdosecytarabinerealworlddatafromgermany AT schmalbrocklaurak genotypeandintensivepretreatmentinfluenceoutcomeofacutemyeloidleukemiapatientstreatedwithvenetoclaxincombinationwithhypomethylatingagentsorlowdosecytarabinerealworlddatafromgermany AT jungpaul genotypeandintensivepretreatmentinfluenceoutcomeofacutemyeloidleukemiapatientstreatedwithvenetoclaxincombinationwithhypomethylatingagentsorlowdosecytarabinerealworlddatafromgermany AT bumederirmgard genotypeandintensivepretreatmentinfluenceoutcomeofacutemyeloidleukemiapatientstreatedwithvenetoclaxincombinationwithhypomethylatingagentsorlowdosecytarabinerealworlddatafromgermany AT kiewephilipp genotypeandintensivepretreatmentinfluenceoutcomeofacutemyeloidleukemiapatientstreatedwithvenetoclaxincombinationwithhypomethylatingagentsorlowdosecytarabinerealworlddatafromgermany AT heckerjudiths genotypeandintensivepretreatmentinfluenceoutcomeofacutemyeloidleukemiapatientstreatedwithvenetoclaxincombinationwithhypomethylatingagentsorlowdosecytarabinerealworlddatafromgermany AT verbeekmareike genotypeandintensivepretreatmentinfluenceoutcomeofacutemyeloidleukemiapatientstreatedwithvenetoclaxincombinationwithhypomethylatingagentsorlowdosecytarabinerealworlddatafromgermany AT westermannjorg genotypeandintensivepretreatmentinfluenceoutcomeofacutemyeloidleukemiapatientstreatedwithvenetoclaxincombinationwithhypomethylatingagentsorlowdosecytarabinerealworlddatafromgermany AT bullingerlars genotypeandintensivepretreatmentinfluenceoutcomeofacutemyeloidleukemiapatientstreatedwithvenetoclaxincombinationwithhypomethylatingagentsorlowdosecytarabinerealworlddatafromgermany AT kellerulrich genotypeandintensivepretreatmentinfluenceoutcomeofacutemyeloidleukemiapatientstreatedwithvenetoclaxincombinationwithhypomethylatingagentsorlowdosecytarabinerealworlddatafromgermany AT bassermannflorian genotypeandintensivepretreatmentinfluenceoutcomeofacutemyeloidleukemiapatientstreatedwithvenetoclaxincombinationwithhypomethylatingagentsorlowdosecytarabinerealworlddatafromgermany AT kronkejan genotypeandintensivepretreatmentinfluenceoutcomeofacutemyeloidleukemiapatientstreatedwithvenetoclaxincombinationwithhypomethylatingagentsorlowdosecytarabinerealworlddatafromgermany AT gotzekatharinas genotypeandintensivepretreatmentinfluenceoutcomeofacutemyeloidleukemiapatientstreatedwithvenetoclaxincombinationwithhypomethylatingagentsorlowdosecytarabinerealworlddatafromgermany AT riegerkathrin genotypeandintensivepretreatmentinfluenceoutcomeofacutemyeloidleukemiapatientstreatedwithvenetoclaxincombinationwithhypomethylatingagentsorlowdosecytarabinerealworlddatafromgermany |